Project Details
| Status | Finished |
|---|---|
| Effective start/end date | 05/16/17 → 12/19/20 |
Funding
- Merck Sharp and Dohme Limited Liability Corporation: $18,714.16
A Randomized Parallel-Group, Placebo-Controlled, Double-Blind, Event-Driven, Multi-Center Pivotal Phase III Clinical Outcome Trial of Efficacy and Safety of the Oral sGC Stimulator Vericiguat in Subjects With Heart Failure With Reduced...
- Skopicki, Hal A (PI)
- Lawson, William (CoPI)
- Bloom, Michelle (CoPI)
- Pilato, Lauren (CoPI)
Project: Research